

Accelerating Medicines Partnership® Program Symposium

February 5-6, 2024 | Bethesda North Marriott Hotel and Conference Center

Final Agenda

Monday, February 5th

8:00-8:55 AM	Registration/Breakfast
9:00-9:15 AM	Welcoming Remarks
	Julie Gerberding, MD, MPH, President and CEO, FNIH Lawrence A. Tabak, D.D.S., Ph.D., Principal Deputy Director, National Institutes of Health
9:15-10:00 AM	Fireside Chat: The Vision and Launch of the AMP Program
	Francis Collins, MD, Ph.D., Distinguished Investigator, National Human Genome Research Institute and former NIH Director David Wholley, Executive Consultant and former Executive Vice President, Business Development, FNIH Courtney Silverthorn, Ph.D., Associate Vice President, Science Partnerships and AMP Director, FNIH
10:00-11:10 AM	AMP Alzheimer's Disease
	The AMP AD session will cover critical aspects of the program, including an overview of goals in both AMP AD 1.0 and AMP AD 2.0. Topics include the impact of sharing clinical trials data, enabling data infrastructure for systems biology research, and a precision medicine approach in AMP AD 2.0. Discussions will also focus on deconstructing disease complexity, integrative proteomics for novel targets, and developing a multi-omic atlas of Alzheimer's disease. These talks aim to provide insights into the program's advancements and contributions.
	<u>Speakers</u> Suzana Petanceska, Ph.D., Program Director, National Institute on Aging Laurie Ryan, Ph.D., Chief of the Clinical Interventions and Diagnostics Branch, Division of Neuroscience, National Institute on Aging Anna Greenwood, Ph.D., Director, Alzheimer's Disease Research Team, Sage Bionetworks

	<p>David Bennett, MD, Director, Rush Alzheimer’s Disease Center, Rush University Medical Center</p> <p>Nick Seyfried, Ph.D., Professor of Biochemistry and Neurology, Director, Emory Integrated Proteomics Core, Emory University</p> <p>Matthias Arnold, Ph.D., Adjunct Associate Professor, Department of Psychiatry and Behavioral Sciences, Duke University & Team Leader, Helmholtz Munich</p> <p>Rebecca Edelmayer, Ph.D., Senior Director, Scientific Engagement, Alzheimer’s Association</p> <p>Michael Nagle, Ph.D., Director, Head of Human Genetics, Eisai</p>
<p>11:10-12:20 PM</p>	<p>AMP Autoimmune and Immune-Mediated Diseases</p>
	<p>The AMP Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) successfully deconstructed, at the single-cell level, cellular states and intracellular pathways to identify cellular populations and effector pathways of autoimmune and immune-mediated disease. AMP Autoimmune and Immune-Mediated Disease Program (AMP AIM) continues to move toward better therapeutic interventions by integrating spatially-informed tissue and blood data to reconstruct cellular environments and interactions to identify causative pathways of disease initiation, progression, and damage in Rheumatoid Arthritis, Psoriatic Spectrum Disorder, Sjögren’s Disease, and Systemic Lupus Erythematosus. The session will spotlight the tangible benefits achieved through AMP research, with insights from clinical research, industry perspectives, and patient impacts. Attendees can also anticipate exciting updates on the future trajectory of these projects.</p>
	<p><u>Speakers</u></p> <p>Robert Carter, MD, Deputy Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases</p> <p>Judith James, MD, Ph.D., Executive Vice President and Chief Medical Officer, Oklahoma Medical Research Foundation</p> <p>Anna Greenwood, Ph.D., Director, Sage Bionetworks</p> <p>Michael B. Brenner, MD, Elizabeth Fay Brigham Professor of Medicine, Harvard Medical School, Director, Cell and Molecular Immunology, Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital</p> <p>Jill Buyon, MD, Director, Division of Rheumatology and Director of the Lupus Center, NYU Grossman School of Medicine</p> <p>Caroline Shiboski, DDS, Ph.D., MPH, Professor, Department of Orofacial Sciences, School of Dentistry, UCSF</p> <p>Jose Scher, MD, Director, NYU Colton Center for Autoimmunity</p> <p>Marc Levesque, MD, PhD, Vice President, Immunology Discovery, Merck</p> <p>Rab Prinjha, Ph.D., Vice President and Head of Adaptive Immunity and Immuno-epigenetics Research Unit, GSK</p>

	Mary Collins, Ph.D., Scientific Advisory Board, Lupus Research Alliance
12:20-1:40 PM	LUNCH/SPEED NETWORKING Structured networking from 1:00-1:35pm where small groups will rotate every 5 minutes, providing the opportunity to meet other conference attendees, interact in diverse groups and identify potential follow-up interactions.
1:40-2:50 PM	AMP Common Metabolic Diseases AMP CMD is built upon the federated knowledge portal developed for AMP T2D and is continuing to expand genetic, genomic and epigenetic data both from the community and data generated through directed efforts of the AMP T2D and AMP CMD SC. This session will begin with a historical perspective on AMP T2D and CMD, followed by updates on several of the active AMP CMD projects and from Pfizer. The session will conclude with a talk from AMP CMD industry partners on the next steps for AMP CMD.
	<u>Speakers</u> Melissa Miller, Ph.D., Senior Director of Human Genetics, Internal Medicine Research Unit, Pfizer Research and Development, Pfizer Norann Zaghoul, Ph.D., Program Director, Division of Diabetes, Endocrinology, & Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, NIH Kyle Gaulton, Ph.D., Associate Professor in the Department of Pediatrics and Winkler Endowed Professor of Type 1 Diabetes, UCSD Tatiana Kisseleva, M.D., Ph.D., Professor of Surgery, UCSD David Brenner, M.D., President and CEO, Sanford Burnham Prebys and Distinguished Professor of Medicine Emeritus, UCSD Panos Roussos, M.D., M.S., Ph.D., Director, Center for Disease Neurogenomics, Icahn School of Medicine at Mt. Sinai Johan Bjorkegren, M.D., Ph.D., Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mt. Sinai Josh Chiou, Ph.D., Senior Principal Computational Geneticist, Pfizer Melissa Thomas, M.D., Ph.D., Vice President-Medical, Diabetes, Obesity, and Complications Research, Eli Lilly and Company
2:50-3:05 PM	BREAK
3:05-4:15 PM	AMP Parkinson's Disease The AMP PD session will address key facets of the program, encompassing an overview of goals within AMP-PD. The session will delve into the construction of

	<p>the AMP-PD platform, highlighting both successful and unsuccessful elements, along with achievements in harmonized data generation for identifying Parkinson's disease biomarkers. These presentations aim to offer valuable insights into the program's progress and contributions.</p>
	<p><u>Speakers</u> Debra Babcock, MD, Ph.D., Program Director, Division of Neuroscience, National Institute of Neurological Disorders and Strokes, NIH Matt Bookman, Solutions Architect and Manager, Verily Panos Roussos, MD, MS, Ph.D., Director, Center for Disease Neurogenomics, Icahn School of Medicine at Mt. Sinai Aparna Vasanth Kumar, Ph.D., Senior Principal Research Scientist, AbbVie Ameya Kulkarni, Ph.D., Senior Scientist, Genomics Research Center, AbbVie David Craig, Ph.D., Vice-Chair, Department of Translational Genomics, USC Keck School of Medicine USC Mary Makarios, National Institute on Aging, NIH</p>
<p>4:15-5:15 PM</p>	<p>Panel Discussion: 10 Years of AMP Impacts</p>
	<p>Since the launch of the AMP program in 2014, these large-scale public-private partnerships have accomplished a number of scientific aims that have had impacts on the broad scientific, medical, and patient communities. This panel will focus on the impacts of the longest-running AMP projects in Alzheimer's Disease, Rheumatoid Arthritis and Lupus, Type 2 Diabetes (launched in 2014) and Parkinson's Disease (launched in 2017).</p>
	<p><u>Moderator</u> Courtney Silverthorn, Ph.D., Associate Vice President, Science Partnerships and AMP Director, FNIH</p> <p><u>Panelists</u> Lindsey Criswell, MD, MPH, DSc, Director, National Institute on Arthritis and Musculoskeletal and Skin Diseases, NIH Richard Hodes, MD, Director, National Institute on Aging, NIH Walter Koroshetz, MD, Director, National Institute of Neurological Disorders and Stroke, NIH Griffin Rodgers, MD, MACP, Director, National Institute of Diabetes and Digestive and Kidney Diseases, NIH Melissa Thomas, MD, Ph.D., Senior Medical Fellow in Diabetes, Obesity, and Complications Research, Lilly Research Laboratories Maria Quinton, Ph.D., Scientific Director, Precision Medicine Neuroscience, AbbVie</p>

5:30-7:15PM	Poster Reception
	Networking for conference recipients and poster presentations showcasing the breadth of research within the AMP program by highlighting the scientific outcomes, impacts, and ongoing work of AMP-funded research from individual AMP program awardees.

Tuesday, February 6th

7:30-8:15 AM	Registration/Breakfast
8:15-8:20AM	Welcome/Recap
	Courtney Silverthorn, Ph.D., Associate Vice President, Science Partnerships and AMP Director, FNIH
8:20-9:30 AM	AMP Heart Failure
	AMP HF will deconstruct the syndrome of heart failure with preserved ejection fraction (HFpEF), classify potential disease subtypes, and identify specific therapeutic targets through tissue-level phenotyping and advanced analytics.
	<p><u>Speakers</u></p> <p>Will Chutkow, MD, Ph.D., Executive Director of Heart Failure Drug Discovery & Systems Biology, Cardiovascular, Renal & Metabolic Diseases, Novartis BioMedical Research</p> <p>Vandana Sachdev, MD, Director, Echocardiography Laboratory, National Heart, Lung, and Blood Institute, NIH</p> <p>Sanjiv Shah, MD, Director, Institute for Artificial Intelligence in Medicine - Center for Deep Phenotyping and Precision Therapeutics</p> <p>Ross Upton, Ph.D., Founder, CEO, CSO, Ultromics</p> <p>Maggie Redfield, MD, Consultant, Division of Circulatory Failure, Department of Cardiovascular Medicine, Professor of Medicine, Mayo Clinic (<i>pre-recorded</i>)</p> <p>Javed Butler, MD, MPH, MBA, President, Baylor Scott and White Research Institute and Senior Vice President, Baylor Scott and White Health, Distinguished Professor of Medicine, University of Mississippi</p> <p>Svati Shah, MD, MHS, Associate Dean for Translational Research, Director, Duke Center for Precision Health, Duke University School of Medicine</p> <p>Cynthia Chauhan, Stage III HFpEF patient (<i>pre-recorded</i>)</p>

9:30-10:25 AM	Panel Discussion: Data, Data, Everywhere – AMP Portals and Interoperability
	<p><u>Moderator</u></p> <p>Susan Gregurick, Ph.D., Associate Director for Data Science and Director, Office of Data Science Strategy, NIH</p> <p><u>Panelists</u></p> <p>Suzana Petanceska, Ph.D., Program Director, National Institute on Aging, NIH Noel Burt, Director, Operations & Development, Diabetes Research & Knowledge Portals in Medical and Population Genetics Program and Metabolism Program, Broad Institute Sweta Ladwa, MPH, PMP, Chief, Scientific Solutions Delivery Branch, Information Technology and Applications Center (ITAC) and Scientific Program Director for BioData Catalyst Data Management Core, NHLBI Technology and Application Center, National Heart, Lung, and Blood Institute, NIH Matt Bookman, Solutions Architect, Verily Anna Greenwood, Ph.D., Director, Alzheimer’s Disease Research Team, Sage Bionetworks</p>
	<p>This panel session will delve into the successes and lessons learned from 10 years of collective effort across the AMP project data portals. There will be a special focus on the AMP Systems Biology of Inflammation's design phase strategy for cross-project data interoperability and integration and the opportunities and challenges involved. Additionally, the panel will showcase presentations from various AMP data portals, offering insights into their data management strategies and highlighting the impactful outcomes of the data generated by these projects. We hope that this session will play a pivotal role in achieving the symposium's broader goals, showcasing scientific progress, and fostering collaborative discussions within the AMP community and the wider scientific network.</p>
10:25-11:35 AM	AMP Bespoke Gene Therapy Consortium
	<p>The Bespoke Gene Therapy Consortium aims to deliver AAV gene therapies to patients suffering from rare monogenic disorders. The project is adapting the regulatory environment by developing minimum standards for analytical testing and preclinical testing of manufactured AAV gene therapy product. These minimum standards, along with learnings from BGTC clinical trials and best practices identified from our team of AAV gene therapy experts, will be coalesced into a gene therapy clinical development playbook, a publicly available resource.</p>

	<p><u>Speakers</u></p> <p>PJ Brooks, Ph.D., Deputy Director, Division of Rare Diseases Research Innovation, National Center for Advancing Translational Sciences, NIH</p> <p>Tim Miller, MD, Vice President, Enterprise Science & Innovation, Thermo Fisher Scientific</p> <p>Peter Marks, MD, Ph.D., Director, Center for Biologics Evaluation and Research, FDA</p> <p>Jean Dehdashti, Ph.D., Program Officer, Division of Rare Diseases Research Innovation, National Center for Advancing Translational Sciences, NIH</p> <p>Amritha Jaishankar, Ph.D., Executive Director, Cell & Gene Therapy (CAGT) Center, IQVIA</p> <p>Carmen Sivakumaren, Ph.D., Manager, Enterprise Transformation Strategy, IQVIA</p> <p>Jenny Fam, Director, MBA, RAC, Director, Regulatory and Drug Development Solutions (RADDs) & Cell & Gene Therapy (CAGT) Center, IQVIA</p>
<p>11:35-12:20 PM</p>	<p>Panel Discussion: FNIH Patient Engagement</p>
	<p>This panel will feature discussion and audience Q&A with members of the FNIH’s Patient Ambassadors Program, providing tangible examples of FNIH’s commitment to patient engagement and enabling best practice sharing across the landscape of AMP programs.</p>
	<p><u>Moderators</u></p> <p>Julie Gerberding, MD, MPH, President and CEO, FNIH</p> <p>Tania Kamphaus, MSc, Ph.D., Director, Translational Science Metabolic Disorders and Director of Patient Engagement, FNIH</p> <p><u>Panelists</u></p> <p>Janet Church, President and CEO, Sjogren’s Foundation (AMP AIM)</p> <p>Terry Pirovolakis, CEO, Elpida Therapeutics and Founder, CureSPG50 (AMP BGTC)</p> <p>Sharon King, Manager, Advocacy and Community Engagement, Alvedron (AMP BGTC)</p> <p>Carlos Larrauri, MSN, National Alliance on Mental Illness (AMP Schizophrenia)</p> <p>Rebecca Edelmayer, Ph.D., Senior Director, Scientific Engagement, Alzheimer’s Association (AMP Alzheimer’s Disease)</p> <p>Maggie Kuhl, Vice President, Research Engagement, The Michael J. Fox Foundation for Parkinson’s Research (AMP Parkinson’s Disease)</p> <p>Will Chutkow, MD, Ph.D., Executive Director of Heart Failure Drug Discovery & Systems Biology, Cardiovascular, Renal & Metabolic Diseases, Novartis BioMedical Research (AMP Heart Failure)</p> <p>Joni Rutter, Ph.D., Director, National Center for Advancing Translational Sciences, NIH (AMP BGTC)</p>

12:20-1:10PM	LUNCH
1:10-2:20 PM	AMP Schizophrenia
	<p>The AMP SCZ session ensures a thorough exploration of the program's key elements. Commencing with a warm welcome and an insightful overview of the AMP SCZ project, we'll establish a foundation for an in-depth discussion on digital assessment strategies and their implementation. Delving further, the session will illuminate the substantial contribution of regulatory science to schizophrenia research, offering a pharmaceutical perspective on unlocking the potential of digital measures. By centering the narrative around patient experience, we breathe life into the story with vivid anecdotes and best practices, infusing authenticity into the unfolding narrative. To conclude, the session invites active participation in an engaging Q&A, empowering participants to shape the ongoing adventure of learning and discovery with their voices.</p>
	<p><u>Speakers</u> Joshua Gordon, MD, Ph.D., Director, National Institute of Mental Health, NIH Justin Baker, MD, Ph.D., Associate Professor of Psychiatry, Harvard Medical School Gahan Pandina, Ph.D., Senior Director, Compound Development Team Leader, Neuroscience at Janssen Research & Development Carlos Larrauri, MSN, National Alliance on Mental Illness Brandon Staglin, MS, President, One Mind Linda Brady, Ph.D., Director, Division of Neuroscience and Basic Behavioral Science, National Institute of Mental Health, NIH Valentina Mantua, MD, Ph.D., Clinical Team Leader, Office of Neuroscience, Division of Psychiatry, CDER, FDA</p>
2:20-3:00 PM	Panel Discussion: Regulatory Engagement in the AMP Program
	<p>This panel discussion will focus on how AMP projects engage with regulators to accelerate therapies and diagnostics through the regulatory process to the patients that need them. We will discuss how public-private partnerships promote innovation and efficiency in the development of regulated products. For example, in rare diseases, regulatory streamlining, data leveraging, and innovative clinical trial designs are among the approaches that may expedite cell and gene therapy products advancement to the clinic.</p>
	<p><u>Moderators</u> Stacey Adam, Ph.D., Associate Vice President, Science Partnerships, FNIH</p>

	<p><u>Panelists</u></p> <p>Norm Stockbridge, MD, Ph.D., Director, Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, FDA Jeff Siegel, MD, Office Director, Office of Drug Evaluation Sciences, FDA Teresa Buracchio, MD, Director, Office of Neuroscience, Center for Drug Evaluation and Research, FDA Gopa Raychaudhuri, Ph.D., Associate Director for Special Programs, Center for Biologics Evaluation and Research, FDA Hilary Marston, MD, MPH, Chief Medical Officer, FDA</p>
3:00-3:15 PM	BREAK
3:15-3:55 PM	Closing Keynote: The Next 10 Years of the AMP Program
	<p>Mikael Dolsten, MD, Ph.D., Chief Scientific Officer and President, Pfizer Research and Development</p>
3:55-4:00 PM	Closing Remarks
	<p>Courtney Silverthorn, Ph.D., Associate Vice President, Science Partnerships and AMP Director, FNIH</p>
4:00-5:30 PM	AMP Leadership Reception (By Invitation)